Castration resistant prostate cancer, beyond the usual treatment

Location: Room 14b (ICM, Level 1)

Chairs: T.A. Borkowski, Warsaw (PL)
S. Egawa, Tokyo (JP)
A. Necchi, Milan (IT)

Aims and objectives of this presentation
The treatment Castration Resistant Prostate Cancer has been revolutionised over the years….Understanding its complexity is a major challenge for most urologists. This session will help understand the latest developments in the area.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

**764**

Radium-223 (Ra-223) re-treatment (re-tx): Experience from an international, multicenter, prospective study in patients (pts) with castration-resistant prostate cancer and bone metastases (mCRPC)

By: Keizman D.¹, Nordquist L.T.², Mariados N.³, Méndez Vidal M.J.⁴, Thellenberg Karlsson C.⁵, Peer A.⁶, Procopio G.⁷, Frank S.J.⁸, Pulkkanen K.⁹, Severi S.¹⁰, Trigo Perez J.M.¹¹, Schwarzenberger P.¹², Li R.¹³, Sartor O.¹⁴

Institutes: ¹Meir Medical Center, Dept. of Genitourinary Oncology Service, Kfar-Saba, Israel, ²GU Research Network, LLC, Dept. of Medical Oncology, Omaha, Nebraska, United States of America, ³Associated Medical Professionals of New York, PLLC, Dept. of Radiation Oncology, Syracuse, New York, United States of America, ⁴Hospital Universitario Reina Sofia, Dept. of Medical Oncology, Cordoba, Spain, ⁵Cancer Center Norrland University, Dept. of Radiation Sciences, Umeå, Sweden, ⁶Rambam Medical Center, Dept. of Oncology, Haifa, Israel, ⁷Foundation IRCCS National Cancer Institute, Dept. of Medical Oncology, Milan, Italy, ⁸Hadassah Hebrew University Medical Center, Dept. of Oncology, Jerusalem, Israel, ⁹Kuopio University Hospital, Dept. of Oncology, Kuopio, Finland, ¹⁰Romagnolo Scientific Institute For The Study and Care of Cancer – IRST IRCCS, Dept. of Nuclear Medicine Therapeutic, Meldola, Italy, ¹¹Hospital Universitario Virgen De La Victoria, Dept. of Medical Oncology, Malaga, Spain, ¹²Bayer HealthCare, Dept. of Global Clinical Development, Whippany, New Jersey, United States of America, ¹³Bayer HealthCare, Dept. of Global Research & Development Statistics, Whippany, New Jersey, United States of America, ¹⁴Tulane Cancer Center, Dept. of Medicine and Urology, New Orleans, Louisiana, United States of America

**765**

Updated long-term efficacy and safety of androgen receptor inhibitor ODM-201 in phase I/II trial

By: Fizazi K.¹, Massard C.¹, Bono P.², Kataja V.³, James N.⁴, Tammela T.⁵, Joensuu H.², Aspegren J.⁶, Mustonen M.V.⁶

Institutes: ¹Institut Gustave Roussy, Dept. of Cancer Medicine, Villejuif, France, ²Helsinki University Central Hospital, Comprehensive Cancer Center, Helsinki, Finland, ³Kuopio University Hospital, Jyväskylä Central Hospital, Kuopio, Finland, ⁴Queen Elizabeth Hospital University Hospitals, Birmingham NHS Foundation Trust, Birmingham, Finland, ⁵Tampere University Hospital, Dept. of Urology, Tampere, Finland, ⁶Orion Corporation Orion Pharma, Research and Development, Espoo, Finland

**766**

Statin use and prostate cancer mortality

By: Benzon Larsen S.¹, Skriver C.¹, Dehleloddorf C.¹, Jespersen C.², Borre M.³, Nørgård M.⁴, Brasso K.⁵, Andersen K.K.¹, Sørensen H.⁴, Hallas J.⁵, Friis S.¹

Institutes: ¹Danish Cancer Society, Research Centre, Copenhagen, Denmark, ²Viborg Hospital, Dept. of Urology, Viborg, Denmark, ³Aarhus University Hospital, Dept. of Urology, Aarhus, Denmark,
*767

**Testosterone bounce predicts cancer specific survival of prostate cancer patients treated with docetaxel therapy**

**By:** Shuhei K.¹, Sakamoto S.², Yamamoto S.¹, Inoue T.¹, Nozumi K.¹, Chiba K.¹, Miyazaki K.¹, Atsushi I.¹, Nagata M.¹

**Institutes:** Yokohama Rosai Hospital, Dept. of Urology, Yokohama City, Kanagawa, Japan,²Chiba Univ. Hospital, Dept. of Urology, Chiba City, Chiba, Japan

*768

**Effect of PSA response on overall and progression-free survival in patients with metastatic castration resistant prostate cancer (mCRPC) treated with cabazitaxel (Caba): The non-interventional study QoLiTime**

**By:** Hammerer P.¹, Al-Batran S-E.², Windemuth-Kieselbach C.³, Hofheinz R.-D.⁴

**Institutes:**¹Academic Hospital Braunschweig, Dept. of Urology and Uro-Oncology, Braunschweig, Germany,²Nordwest Hospital, Institute of Clinical Research, Frankfurt, Germany,³Alcedis GmbH, Dept. of Biometry, Gießen, Germany,⁴University Hospital Mannheim, Interdisciplinary Tumor Center, Mannheim, Germany

*769

**Initial clinical experience with 177Lu-PSMA I&T radionuclide therapy in patients with metastatic castration-resistant prostate cancer**

**By:** Heck M.¹, Retz M.¹, Rauscher I.², Scheidhauer K.², Maurer T.¹, Storz E.¹, Janssen F.¹, D’Alessandria C.², Wester H.-J.³, Gschwend J.E.¹, Schwaiger M.², Tauber R.¹, Eber M.²

**Institutes:**¹Klinikum Rechts der Isar der Technischen Universität München, Dept. of Urology, Munich, Germany,²Klinikum Rechts der Isar der Technischen Universität München, Dept. of Nuclear Medicine, Munich, Germany,³Technische Universität München, Dept. of Pharmaceutical Radiochemistry, Garching, Germany

*770

**Hormonal response after long-term androgen suppression in patients with prostate cancer**

**By:** Planas Morin J.¹, Celma A.¹, Regis L.¹, Cuadras M.¹, Trilla E.¹, Salvador C.¹, Placer J.¹, Lorente D.¹, Carles J.², Suárez C.³, Morote J.¹

**Institutes:**¹Hospital Universitari Vall d’Hebron, Dept. of Urology, Barcelona, Spain,²Hospital Universitari Vall d’Hebron, Dept. of Oncology, Barcelona, Spain

*771

**Real-world treatment patterns and factors influencing the use of bone-targeted agents (BTAs) in combination with emerging therapeutics in patients with prostate cancer and bone-metastases**

**By:** Body J-J.¹, Von Moos R.², Rider A.³, Bhowmik D.⁴, Hallworth P.⁵, Hechmati G.⁶, Qian Y.⁷, Gatta F.⁸

**Institutes:**¹Chu Brugmann, Dept. Of Medicine, Brussels, Belgium,²Kantonsspital Graubünden, Dept. of Oncology, Chur, Switzerland,³Adelphi Real World, Bollington, United Kingdom,⁴Amgen Inc., Dept. of Health Economics, Thousand Oaks, United States of America,⁵Amgen (Europe) GmbH, Dept. of Health Economics, Zug, Switzerland

*772

**Which factors predict overall survival in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate post-docetaxel?**


**Institutes:**¹Ghent University Hospital, Dept. of Urology, Ghent, Belgium,²Ghent University Hospital, Dept. of Medical Oncology, Ghent, Belgium,³Leuven University Hospital, Dept. of Medical Oncology, Leuven, Belgium,⁴AZ Turnhout, Dept. of Medical Oncology, Turnhout, Belgium,⁵AZ Klinia, Dept. of Medical Oncology, Brasschaat, Belgium,⁶AZ Delta, Dept. of Medical Oncology, Roeselare, Belgium,⁷AZ Imelda, Dept. of Medical Oncology, Bonheiden, Belgium,⁸Institut Jules Bordet, Dept. of Medical Oncology, Brussels, Belgium,⁹OLV Aalst, Dept. of Urology, Aalst, Belgium,¹⁰Hopital De Jolimont, Dept. of Medical Oncology, Haine Saint Paul, Belgium,¹¹Brussels University Hospital, Dept. of Medical Oncology, Brussels, Belgium,¹²Cliniques Universitaires Saint Luc, Dept. of
**Abiraterone for castration resistant prostate cancer: Adherence, survival and hospitalization: Analysis of a medical claims database**

By: Mohamad Al-Ali B.¹, Madersbacher S.¹, Berger I.²

Institutes: ¹Kaiser-Franz-Josef Spital, Dept. of Urology and Andrology, Vienna, Austria, ²Klinikum Wiener Neustadt, Dept. of Urology and Andrology, Wiener Neustadt, Austria

**ARV7 detected by a novel whole-blood RT-PCR assay correlates with outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate (ABI)**

By: Todenhöfer T.¹, Azad A.², Gao J.¹, Stewart C.¹, Eigl B.², Stenzl A.⁴, Black P.¹, Teich M.³, Joshua A.³, Chi K.²

Institutes: ¹University of British Columbia, Vancouver Prostate Centre, Vancouver, Canada, ²British Columbia Cancer Agency, Dept. of Medical Oncology, Vancouver, Canada, ³University of Toronto, Princess Margret Cancer Centre, Toronto, Canada, ⁴Eberhard-Karls-University, Dept. of Urology, Tübingen, Germany

**The phase 3 COU-AA-302 study of abiraterone acetate (AA) in men with chemotherapy (CT)-naïve metastatic castration-resistant prostate cancer (mCRPC): Stratified analysis based on pain, prostate-specific antigen (PSA) and Gleason score (GS)**

By: Miller K.¹, Carles J.², Gschwend J.E.³, Van Poppel H.⁴, Diels J.⁵, Brookman-May S.D.⁶

Institutes: ¹Charité Berlin, Dept. of Urology, Berlin, Germany, ²Vall d’Hebron University Hospital, Dept. of Medical Oncology, Barcelona, Spain, ³Technical University of Munich, School of Medicine, Munich, Germany, ⁴Katholieke Universiteit Leuven, Dept. of Urology, Leuven, Belgium, ⁵Janssen EMEA, HEMAR, Beerse, Belgium, ⁶Ludwig Maximilians University of Munich, Janssen Research & Development, Munich, Germany